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Background and purpose: Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma
high density lipoprotein (HDL) cholesterol levels but is associated with increased blood pressure. In a phase 3 clinical study,
evaluating the effects of torcetrapib in atherosclerosis, there was an excess of deaths and adverse cardiovascular events in
patients taking torcetrapib. The studies reported herein sought to evaluate off-target effects of torcetrapib.
Experimental approach: Cardiovascular effects of the CETP inhibitors torcetrapib and anacetrapib were evaluated in animal
models.
Key results: Torcetrapib evoked an acute increase in blood pressure in all species evaluated whereas no increase was observed
with anacetrapib. The pressor effect of torcetrapib was not diminished in the presence of adrenoceptor, angiotensin II or
endothelin receptor antagonists. Torcetrapib did not have a contractile effect on vascular smooth muscle suggesting its effects
in vivo are via the release of a secondary mediator. Treatment with torcetrapib was associated with an increase in plasma levels
of aldosterone and corticosterone and, in vitro, was shown to release aldosterone from adrenocortical cells. Increased adrenal
steroid levels were not observed with anacetrapib. Inhibition of adrenal steroid synthesis did not inhibit the pressor response to
torcetrapib whereas adrenalectomy prevented the ability of torcetrapib to increase blood pressure in rats.
Conclusions and implications: Torcetrapib evoked an acute increase in blood pressure and an acute increase in plasma
adrenal steroids. The acute pressor response to torcetrapib was not mediated by adrenal steroids but was dependent on intact
adrenal glands.
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Introduction
The use of statins for lowering low-density lipoprotein (LDL)
in humans has unequivocally been demonstrated to reduce
the incidence of cardiovascular disease and increase long-
evity (Scandinavian Simvastatin Survival Study Group, 1994;
Sacks et al., 1996; Long-Term Intervention with Pravastatin
in Ischaemic Disease (LIPID) Study Group, 1998; Sever et al.,
2003). However, it is equally evident that greater clinical
benefit can be achieved given that, at best, statins reduce the
risk of major coronary events by only 30% (LaRosa et al.,
1999; Maron et al., 2000). An alternative therapeutic strategy
being pursued by many pharmaceutical companies is to
increase circulating levels of high-density lipoprotein (HDL).
This strategy is predicated on the strong epidemiologic data
that document an inverse correlation between HDL levels
and coronary heart disease (Gordon et al., 1989; Assmann
and Schulte, 1992).
A novel pharmacological approach for elevation of HDL
levels is the use of inhibitors of cholesteryl ester transfer
protein (CETP). Inhibitors of CETP prevent the transfer of
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lipoprotein and the reciprocal transfer of triglycerides from
LDL and very low-density lipoprotein to HDL. Numerous
preclinical and clinical studies confirm that CETP inhibitors
effectively increase circulating HDL levels (Barter et al., 2003;
Brousseau et al., 2004; Clark et al., 2004; Davidson et al.,
2006). Furthermore, preclinical studies with CETP inhibitors
demonstrated beneficial antiatherosclerotic effects in animal
models (Sugano et al., 1998; Okamoto et al., 2000).
The only human clinical trial to evaluate the effects of a
CETP inhibitor on cardiovascular events is the Investigation
of Lipid Level Management to Understand Its Impact in
Atherosclerotic Events (ILLUMINATE) trial. In this study, the
effect of a CETP inhibitor, torcetrapib (Pfizer, New York, NY,
USA), in combination with atorvastatin was compared to
treatment with atorvastatin alone. Unfortunately, the study
was terminated prematurely because of an unexpected
increase in cardiovascular events and death with the
combination treatment versus atorvastatin alone (Barter
et al., 2007). The reason(s) for the increase in mortality is
not known; however, it is known that torcetrapib adminis-
tration in humans is associated with an increase in blood
pressure (Davidson et al., 2006; Barter et al., 2007; Nissen
et al., 2007). Furthermore, examination of serum electrolyte
values from the ILLUMINATE study revealed a decrease in
potassium and increases in sodium and bicarbonate at the
end of 12 months in patients taking torcetrapib plus
atorvastatin compared with those taking atorvastatin alone.
These findings prompted a post hoc examination of aldoster-
one levels, which were shown to be higher in patients who
had taken torcetrapib for 3 months.
The studies described herein evaluate the acute haemo-
dynamic effects of torcetrapib in a variety of preclinical
models and species and compare the effects of torcetrapib
with another experimental CETP inhibitor, anacetrapib
(MK-0859). Administration of torcetrapib was shown to
acutely increase blood pressure in both rodent and non-
rodent species. In addition, in rats, administration of torce-
trapib was associated with the release of aldosterone and
corticosterone in vivo and in vitro from primary adrenocortical
cells. The other CETP inhibitor, anacetrapib, did not increase
blood pressure under equivalent conditions and was not
associated with adrenal steroid release either in vivo or in vitro.
Methods
Animals
All animals were maintained in AAALAC (Association for
Assessment and Accreditation of Laboratory Animal Care)-
accredited facilities at Merck Research Laboratories (Rahway,
NJ, USA or West Point, PA, USA), and all experimental
procedures were approved by the Institutional Animal Care
and Use Committee and were in conformance with the
National Research Council’s Guide for the Care and Use of
Laboratory Animals.
C57BL/6NTac mice (B6) were purchased from Taconic
(Hudson, NY, USA); C57BL/6-Tg(CETP)1Pnu/J mice
(B6-Tg(CETP)) were purchased from Jackson (Bar Harbor,
ME, USA) and bred at Merck Research Laboratories. Male
Sprague–Dawley rats (300–400g body weight) with surgically
implanted femoral artery and vein catheters were obtained
from Charles River Laboratories (Raleigh, NC, USA). Male or
female mixed breed mongrel dogs (approximately 8–12kg)
were obtained from either Covance Research Products Inc.
(Cumberland, VA, USA) or Marshall BioResources (North
Rose, NY, USA). Male rhesus monkeys (approximately 4–6
years old, body weight 6.5–7.5kg) were obtained from
Covance Research Products Inc. (Alice, TX, USA).
Haemodynamics
Heart rate and blood pressure were measured in mice, rats,
dogs and rhesus monkeys under a variety of experimental
conditions.
For the assessment of cardiovascular function in conscious
mice, animals were surgically implanted with catheters in a
carotid artery and a jugular vein at least 24h prior to study.
On the day of study a Becton Dickinson (Franklin Lakes, NJ,
USA) DTX pressure transducer was attached to the arterial
catheter and subsequently to a Gould ACQ-7700 data
acquisition system using Ponemah software. Heart rate was
derived from the arterial pulse wave. Heart rate and arterial
pressure were measured between 30 and 60min to establish
baseline values. Subsequently, test compound or vehicle (2%
dimethyl sulphoxide:4% Cremophor EL:94% saline) was
administered in a volume of 0.2mL per mouse via a 30min
infusion. Cardiovascular data were recorded continuously
and are reported as average values over 1min intervals.
Equivalent procedures were used for the measurement of
haemodynamics in rats, with the exception that studies were
performed in anaesthetized animals (sodium pentobarbital;
55mgkg
 1, i.p.). In some studies, rats were pithed according
to the method of Gillespie et al. (1970). Test compound or
vehicle (2% dimethyl sulphoxide:4% Cremophor EL:94%
saline or 50% dimethylacetamide:50% polyethylene glycol
200) was administered in a volume of 1mL per rat via an i.v.
infusion of 20–30min duration.
Haemodynamic studies were performed in dogs anaesthe-
tized with sodium pentobarbital (35mgkg
 1, i.v. loading
dose plus 6mgkg
 1h
 1 maintenance infusion). An endo-
tracheal tube was inserted into the trachea and artificial
respiration with ambient room air was employed utilizing a
large animal ventilator (Harvard Apparatus, Boston, MA,
USA). Body temperature was maintained using an automated
heating surgical table and infrared lamp. Bilateral femoral
vein catheters were implanted for the i.v. administration of
anaesthetics and test compounds. Arterial blood pressure was
captured via a catheter inserted into a femoral artery and
connected to a disposable type pressure transducer. Heart rate
was derived from the pulsatile blood pressure or from the ECG
signal. A CA Recorder Systems (DISS LLC) data acquisition
system was used to collect and analyse input signals.
Haemodynamic parameters were collected from conscious
rhesus monkeys implanted with Konigsberg cardiovascular
total implants. Data were transmitted via radiotelemetry and
recorded by CA Recorder Systems (DISS LLC). Arterial blood
pressure and heart rate were collected for X24h prior to
vehicle dosing, X2h prior to oral dosing with test
compound and X24h postdosing. Data were collected as
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s.e. of the mean.
Adrenalectomy
Rats were anaesthetized with sodium pentobarbital
(55mgkg
 1, i.p.). The back of the animal was shaved and a
1.5-cm dorsal midline incision made with its midpoint
centered over the thirteenth rib. The underlying muscle wall
on either side of the spinal column was dissected, and the
adrenal glands were located and removed. Skin incisions
were closed with stainless steel wound clips and acute
haemodynamic measurements made as described above.
Isolated vascular tissue experiments
The descending thoracic aorta was removed from rats, cleaned
of connective tissue and cut into 3mm rings. The endothe-
lium was left intact, and rings were subsequently mounted
(using stainless steel triangle mounts) in 5mL isolated organ
chambers (Radnoti Glass, Monrovia, CA, USA) containing
modified Krebs solution (in mM: 120 NaCl, 5.9 KCl, 2.5 CaCl2,
1.2 MgSO4,1 . 2K H 2PO4,2 5N a H C O 3,1 0g l u c o s e )a t3 7 1Ca n d
aerated with 95%O2:5%CO2. Mounted rings were connected
to isometric force transducers (Radnoti Glass). Passive tension
was set to an optimal resting tension of 0.5–1g, and rings were
allowed to equilibrate for 30min. Isometric tension was
monitored and recorded using IOX data acquisition software
(EMKA Technologies Inc., Falls Church, VA, USA). Rings were
tested for viability using 120mM KCl, washed and allowed to
re-equilibrate for an additional 30min before performing
concentration–response curves to test compounds.
Perfused hindlimb preparation
Rats were anaesthetized with urethane (800mgkg
 1, i.p.)
and a-chloralose (40mgkg
 1, i.p.). A midline incision (3cm
long) was made in the lower abdomen to expose the
bifurcation of the abdominal aorta. The right iliac artery
and vein were isolated and cannulated with modified PE-50
catheters. The arterial catheter was connected to a peristaltic
pump (ML 172; ADInstruments, Newton, NH, USA), the
speed of which was set to generate a perfusion pressure of
60–70mmHg. Perfusion pressure was monitored using a
pressure transducer (DTX plus TNF-R; Becton Dickinson)
connected to a side arm of the arterial catheter. Initially, the
hindlimb was perfused with buffer alone (Krebs-Henseleit
solution) to obtain a steady baseline. Subsequently, the
hindlimb was sequentially perfused with torcetrapib (3–
30mM) followed by phenylephrine (5mM), each for a duration
of 5min with a 2min interval between treatments. The
pressure signal was captured by a Ponemah physiological
data acquisition system (P3 Plus; Data Science International,
St Paul, MN, USA). Mean perfusion pressure was derived by
the software automatically and recorded continuously
throughout the study.
Measurement of plasma adrenal steroids
Adrenal steroid concentrations in plasma samples were
determined using commercially available ELISA kits. The
aldosterone assay was obtained from Alpha Diagnostics (San
Antonio, TX, USA) and the corticosterone assay from
Cayman Chemical Company (Ann Arbor, MI, USA).
Adrenal steroid release assay
The procedure for isolating rat adrenal cells was developed
by modifying previously published methods (Fredlund et al.,
1975). Adrenal glands were removed from male rats,
asphyxiated by CO2 and placed in ice-cold Dulbecco’s
phosphate-buffered saline. The glands were dissected free
of all fat and connective tissue. Each gland was dissected in
half, and the outer capsule separated. Each capsule was
placed in 1.2mL of room temperature medium (one part
Krebs-Ringer bicarbonate (mM: 120 NaCl, 4.6 KCl, 0.5 MgCl2,
0.7 Na2HPO4, 1.5 NaH2PO4, 10 glucose) with two parts
Medium-199 and two parts L-15 plus 5mM HEPES) contain-
ing collagenase (2mgmL
 1) and DNAse (0.4mgmL
 1). The
capsules were teased apart in this solution and incubated
with gentle rocking for 70min at room temperature. Every
20min, cells were gently dispersed by drawing the solution
up and down into a silicon tubing of 10inch length. The
suspensions were washed twice in Dulbecco’s phosphate
buffered saline following centrifugation at 100g for 10min.
Finally, the cells were re-suspended in 1.0mL medium
containing BSA (4mgmL
 1) and soybean trypsin inhibitor
(2mgmL
 1). The final cell concentration was approximately
200000 cells per mL. Cell suspensions (500mL per well) were
placed in a 24-well polystyrene plate to which stimuli were
added. The plate was incubated in a water bath at 371C for
2h. Cell suspensions were centrifuged at 1000g for 10min,
and the media assayed for aldosterone and corticosterone as
described above.
Test compounds
Torcetrapib, anacetrapib and E-3174 were synthesized at
Merck Research Laboratories. The endothelin (ETA/ETB)
antagonist, compound A (Nishikibe et al., 1999), was
synthesized at Banyu Pharmaceuticals, Tsukuba, Japan.
Trilostane was purchased from Chempacific (Baltimore,
MD, USA).
Results
Effects of CETP inhibitors on vascular haemodynamics
The effects of torcetrapib and anacetrapib on blood pressure
were evaluated in normal mice that do not contain CETP and
in transgenic mice expressing the cynomologus CETP gene
(Figure 1). Administration of torcetrapib (10mgkg
 1) by i.v.
infusion of 30min duration evoked a significant increase in
mean arterial blood pressure of approximately 15mmHg.
The increase in blood pressure was transient, returning to
near baseline levels by the conclusion of the infusion. In
both normal B6 mice and B6-Tg(CETP) mice, heart rate
decreased transiently by approximately 20% (data not
shown) following administration of torcetrapib, presumably
a reflexogenic response to the increase in blood pressure.
In contrast, administration of anacetrapib (10mgkg
 1)o r
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was without effect on either blood pressure or heart rate. The
lack of effect of anacetrapib on blood pressure cannot be
explained on the basis of an insufficient dose of anacetrapib
for the following reasons. In the study shown in Figure 1, the
two compounds achieved comparable systemic exposure: in
the wild-type mice, terminal compound levels were 23±4mM
of torcetrapib and 25±3mM of anacetrapib. In the transgenic
mice, the relevant values were 12±7mM of torcetrapib and
9±3mM of anacetrapib. Furthermore, the two compounds
have similar intrinsic potencies against CETP. In an in vitro
fluorogenic assay of CETP activity (Eveland et al., 2007),
torcetrapib had an IC50 of 13±3n M (n¼9) and anacetrapib
had an IC50 of 17±5n M (n¼10). The two compounds also
have similar potencies in vivo. In a study using the same
strain of B6-Tg(CETP) mice used in Figure 1, 2 weeks of
dosing of each compound (10 mice per group) at approxi-
mately 50mgkg
 1 (p.o.) yielded substantial increases in HDL
compared to control animals: 214±54% for torcetrapib and
318±51% for anacetrapib. In this 2-week study, terminal
compound levels were also comparable: 4.6±3.2mM for
torcetrapib and 9.4±3.1mM for anacetrapib.
The effects of torcetrapib on blood pressure and heart rate
were also evaluated in rats, dogs and rhesus monkeys,
whereas anacetrapib was evaluated only in dogs and rhesus
monkeys (Supplementary Figures 1–3). Torcetrapib increased
mean arterial pressure in anaesthetized rats (5mgkg
 1, i.v.),
anaesthetized dogs (1–10mgkg
 1, i.v.) and in conscious
rhesus monkeys (500mgkg
 1, p.o.). Interestingly, torcetra-
pib had no effect on heart rate in either rats or rhesus
monkeys but did produce increases in heart rate of
approximately 35% in anaesthetized dogs. Anacetrapib was
without effect on haemodynamic parameters in either dogs
(1–10mgkg
 1, i.v.) or rhesus monkeys (500mgkg
 1, p.o.).
Torcetrapib did not directly contract vascular smooth muscle
A series of studies was performed to investigate the mechan-
ism by which torcetrapib increases blood pressure. The
ability of torcetrapib to directly contract vascular smooth
muscle was evaluated using both isolated vascular smooth
muscle preparations as well as a rat perfused hindlimb
preparation. Torcetrapib (10
 9–10
 5 M) did not exhibit any
contractile activity when added to isolated rat aortic rings or
isolated rat mesenteric artery rings, whereas methoxamine
(10
 6 M) evoked a robust contractile response of either aortic
or mesenteric artery rings (data not shown). Furthermore,
torcetrapib neither enhanced the contractile response to
a-adrenoceptor agonists or angiotensin II nor reduced the
relaxant effect of ACh (data not shown). In a perfused rat
hindlimb preparation (Figure 2), torcetrapib (3–30mM) had
no effect on perfusion pressure, whereas phenylephrine
evoked a marked increase in perfusion pressure.
Figure 2 Torcetrapib did not increase perfusion pressure in the
isolated perfused rat hindlimb. The effects of torcetrapib or vehicle
on perfusion pressure were evaluated in urethane (800mgkg
 1,
i.p.)- and a-chloralose (40mgkg
 1, i.p.)-anaesthetized rats. The
femoral artery was cannulated and connected to a perfusion pump
at a rate that produced a resting perfusion pressure of B65mmHg.
Subsequently, animals were infused sequentially with torcetrapib
(3–30mM) followed by phenylephrine (5mM). Each data point is the
mean of determinations made in two animals.
Figure 1 Torcetrapib increased blood pressure in normal and CETP
transgenic mice. Mean arterial blood pressure was measured in
conscious B6 mice and B6-Tg(CETP) transgenic mice. Torcetrapib
(10mgkg
 1) or anacetrapib (10mgkg
 1) was administered as an
i.v. infusion of 30min duration. Blood pressure was monitored
continuously and is shown as average values at 1min intervals. Each
point represents the mean, and vertical lines represent the s.e.
Numbers of animals per group are shown in parentheses. CETP,
cholesteryl ester transfer protein.
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mechanism, via sympathetic nervous system activation or via
activation of angiotensin type I or endothelin receptors
The possible central effects of torcetrapib, for elevation of
blood pressure in rats, were evaluated by performing studies
in control animals or in pithed rats. The acute administra-
tion of torcetrapib (5mgkg
 1, i.v.), infused over a 30-min
time period, produced an equivalent increase in blood
pressure in control and pithed rats (Supplementary Figure
4), indicating that torcetrapib was not increasing blood
pressure via a central mechanism. In dogs, pretreatment with
the a1-adrenoceptor antagonist (prazosin; 1mgkg
 1) or the
b1-adrenoceptor antagonist (atenolol; 3mgkg
 1) did not
attenuate the pressor response to torcetrapib (Supplementary
Figures 5a and 6a). Atenolol partly reduced the torcetrapib-
evoked increase in heart rate (Supplementary Figure 6b),
whereas hexamethonium (3mgkg
 1) completely suppressed
the increase in heart rate (Supplementary Figure 7b) but with
only a minor reduction in the pressor response (Supplemen-
tary Figure 7a). A similar lack of effect of prazosin or
phentolamine, to reduce the pressor response to torcetrapib,
was observed in rats (data not shown). The pressor response
to torcetrapib (10mgkg
 1, i.v.) was not reduced in rats
pretreated with either a mixed ETA/B receptor antagonist
(compound A; 3mgkg
 1, i.v.; Figure 3a) or an angiotensin II
receptor blocker (E-3174; 1mgkg
 1, i.v.; Figure 3b).
Evaluation of adrenal steroid levels in rats following
administration of CETP inhibitors
To explore other potential mediators that could account for
the hypertensive effects observed with torcetrapib, plasma
levels of aldosterone prior to and after i.v. infusion of either
torcetrapib or anacetrapib to conscious rats were measured.
Administration of torcetrapib (20mgkg
 1) by i.v. infusion
for 30min evoked a significant (Po0.01) increase in plasma
aldosterone (Figure 4a) from baseline values to those
measured 20min post initiation of compound infusion and
remained elevated for 30min after completion of the
infusion. In contrast to torcetrapib, neither vehicle nor
anacetrapib evoked significant changes in plasma aldo-
sterone levels. Subsequent studies demonstrated that the
Figure 3 Effects of endothelin or angiotensin II receptor antago-
nists. Mean arterial blood pressure was measured in pentobarbital
(55mgkg
 1, i.p.)-anaesthetized rats. (a) Separate groups of animals
were given either the ETA/ETB antagonist, compound A (3mgkg
 1,
i.v.) or vehicle (saline) 60min prior to the i.v. infusion of torcetrapib
(10mgkg
 1) in a volume of 1mL per rat, over 30min. Data are
expressed as the change in pressure from the baseline period 20–
40min prior to test compound infusion. Each point represents the
mean, and vertical lines represent the s.e. for groups of five rats each.
(b) Mean arterial blood pressure was measured in pentobarbital
(55mgkg
 1, i.p.)-anaesthetized rats. Separate groups of animals
were given either the AT1 receptor antagonist, E-3174 (1mgkg
 1,
i.v.) or vehicle (saline) 60min prior to the i.v. infusion of torcetrapib
(10mgkg
 1) in a volume of 1mL per rat over 30min. Data are
expressed as the change in blood pressure from the baseline period
20–40min (D mean BP) prior to giving test compounds. Each point
represents the mean, and vertical lines represent the s.e. for groups
of four rats each.
Figure 4 Measurement of adrenal steroids. (a) Plasma levels of
aldosterone were measured in plasma from conscious rats prior to
and at the indicated times following the i.v. infusion of compounds
at 20mgkg
 1 or vehicle (50% dimethylacetamide:50% polyethy-
lene glycol 200) for 20min. Each data point is the mean and vertical
lines represent the s.e. for the numbers of animals indicated in
parentheses. (b) Plasma levels of corticosterone were measured in
plasma from conscious rats 20min following the i.v. infusion of
compounds at 5mgkg
 1 or vehicle (50% dimethylacetamide:50%
polyethylene glycol 200) for 20min. Each data point is the mean and
vertical lines represent the s.e. for the numbers of animals indicated
in parentheses.
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release as plasma corticosterone levels were also increased
in animals that received torcetrapib (Figure 4b) but not
following administration of anacetrapib.
Pressor responses to torcetrapib are absent in adrenalectomized
rats
Having observed an acute increase in plasma aldosterone and
corticosterone in response to administration of torcetrapib,
we sought to explore further the relationship between adrenal
steroids and the acute hypertensive response to torcetrapib.
In acutely adrenalectomized, anaesthetized rats, torcetrapib
(5mgkg
 1, i.v. infused over 30min) did not increase blood
pressure, whereas administration of torcetrapib to sham-
operated animals evoked a robust pressor response (Figure 5).
Pressor responses to acute angiotensin II challenge
(50ngkg
 1, i.v.) were equivalent in both adrenalectomized
and sham-operated animals (data not shown). At the conclu-
sion of torcetrapib infusion, plasma aldosterone levels were
488±101pgmL
 1 in sham-operated animals and
126±17pgmL
 1 (mean±s.e.mean, n¼7) in acutely adrena-
lectomized animals. The relationship between the acute
pressor effect of torcetrapib and the release of aldosterone
and corticosterone was explored by administration of the 3b-
hydroxysteroid dehydrogenase inhibitor, trilostane. Torcetra-
pib (5mgkg
 1, i.v.) evoked equivalent increases in blood
pressure (Figure 6a) in animals administered trilostane or
control animals administered vehicle (50% DMA:50%
PEG200). However, trilostane completely inhibited the torce-
trapib-induced increase in plasma aldosterone (Figure 6b) and
plasma corticosterone (Figure 6c). Furthermore, administra-
tion of exogenous aldosterone (1 and 10mgkg
 1)t or a t sd i d
not increase blood pressure, whereas administration of
torcetrapib (5mgkg
 1) to these same animals evoked a robust
increase in blood pressure of 10–15mmHg (Figure 7).
Effects on isolated primary adrenocortical cells
The mechanism of torcetrapib-evoked aldosterone release
in vivo is not known. Possibilities include a direct secretago-
gue action of torcetrapib or an indirect effect via known
stimuli such as angiotensin II, adrenocorticotrophic hor-
mone or potassium. To determine if torcetrapib has a direct
effect on the adrenal gland, primary adrenocortical cells were
isolated from rat adrenal glands and exposed in vitro to either
torcetrapib (Figure 8a) or anacetrapib (Figure 8b). Angio-
tensin II (0.1mM) served as a positive control and produced a
robust increase in aldosterone release into the medium.
Torcetrapib also stimulated aldosterone release, whereas
Figure 5 Adrenalectomy prevented the pressor response to
torcetrapib. The effects of torcetrapib infusion (5mgkg
 1 20min)
or vehicle (2% DMSO:4% Cremophor EL:94% saline) on mean
arterial pressure were evaluated in pentobarbital (55mgkg
 1, i.p.)-
anaesthetized rats following acute adrenalectomy or in animals that
were sham-operated. Data are expressed as the change in blood
pressure (D mean BP) from the baseline period 20min prior to giving
test compounds. Each point represents the mean and vertical lines
represent the s.e. for groups of six to nine animals. DMSO, dimethyl
sulphoxide.
Figure 6 3b-hydroxysteroid dehydrogenase inhibition does not
block the pressor effect of torcetrapib. (a) The effects of torcetrapib
infusion (5mgkg
 1 30min) or vehicle (2% DMSO:4% Cremophor
EL:94% saline) on mean arterial pressure were evaluated in conscious
rats 60min after the administration of trilostane (10mgkg
 1, i.v.) or
an equivalent volume (1mLkg
 1) of vehicle (50% dimethylaceta-
mide:50% polyethylene glycol 200). Data are expressed as the
change in blood pressure (D mean BP) from the baseline period 15–
30min prior to giving test compounds. Each point represents the
mean and vertical lines represent the s.e. for groups of eight animals.
(b) Plasma levels of aldosterone were measured in a subgroup (n¼4)
of the animals in (a). Plasma samples were prepared from blood
obtained at the conclusion of the infusion of torcetrapib or vehicle.
(c) Plasma levels of corticosterone were measured in a subgroup
(n¼4) of the animals in (a). Plasma samples were prepared from
blood obtained at the conclusion of the infusion of torcetrapib or
vehicle. DMSO, dimethyl sulphoxide.
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10mM. Attempts to measure corticosterone levels by enzyme
immunoassay in isolated adrenal cells were not successful
using torcetrapib, anacetrapib or angiotensin II as agonists.
Discussion
Reduction of circulating LDL levels through the use of statins
is a mainstay of the pharmacological management of
atherosclerosis. However, despite their unequivocal efficacy,
there is still considerable room for additional cardiovascular
risk reduction in patients. Raising plasma HDL levels is an
attractive objective to complement LDL-lowering drugs,
particularly in light of the strong epidemiological relation-
ship between increased HDL levels and reduced cardiovas-
cular risk. There exist many potential strategies by which
levels of HDL can be increased. Recently, in phase I and II
studies, CETP inhibitors produced robust dose-dependent
elevation of HDL levels (Grooth et al., 2002; Clark et al.,
2004). However, early clinical studies with the CETP
inhibitor torcetrapib, either alone or in combination with
atorvastatin, demonstrated mild increases in systolic and
diastolic blood pressure in humans (Davidson et al., 2006;
McKenney et al., 2006). More recently, a phase III study of
torcetrapib in combination with atorvastatin was terminated
prematurely after approximately 18 months when the
incidence of serious cardiovascular events, including death,
was greater in the torcetrapib–atorvastatin group compared
with subjects receiving atorvastatin alone (Barter et al.,
2007). In this phase III study, there was also reported an
increase in blood pressure and hypertensive adverse events
in patients treated with torcetrapib. An evaluation of serum
electrolytes revealed a decrease in serum potassium and
increases in serum sodium and bicarbonate. The biochemical
changes, along with the increase in blood pressure, suggested
a possible mineralocorticoid excess that was further sub-
stantiated by determining increases in serum aldosterone. In
the present study, we report an acute increase in blood
pressure following torcetrapib administration in a variety of
preclinical animal species. Furthermore, we showed that
torcetrapib administration caused an acute increase in
plasma aldosterone and corticosterone levels in rats and
that torcetrapib released aldosterone via a direct action on
rat adrenocortical cells.
The blood pressure response to torcetrapib is independent of
inhibition of CETP. This conclusion is derived from two lines
of evidence. The first is from data obtained with normal mice
that do not express CETP and a line of transgenic mice
expressing simian CETP. Torcetrapib increases HDL levels in
the CETP transgenic mice but not in normal mice. However,
torcetrapib increased blood pressure to an equivalent extent in
both normal and CETP transgenic mice. The second line of
evidence is that anacetrapib raises HDL to an equivalent extent
as torcetrapib in CETP transgenic mice and at similar exposure
levels as torcetrapib but, in contrast to torcetrapib, anacetrapib
has no effect on blood pressure in either strain of mouse.
Our observation that anacetrapib does not increase plasma
adrenal steroids, at exposures that increase plasma HDL
levels, strongly suggests that the mechanism of torcetrapib-
induced adrenal steroid elevation is also not via a mechan-
ism dependent on CETP inhibition. This was further
substantiated by demonstrating that torcetrapib can directly
release aldosterone from cultured primary rat adrenocortical
cells in vitro in the absence of serum. Furthermore, anace-
trapib had no effect on aldosterone release in this in vitro
assay. The biochemical pathway(s) by which torcetrapib
evokes aldosterone release are under investigation. Although
the first biochemical step in the synthesis of aldosterone is
the conversion of cholesterol to pregnenolone, the true rate-
limiting step of hormone-stimulated steroidogenesis is the
delivery of the substrate, cholesterol, to the inner mitochon-
drial membrane (Stoccco and Clark, 1996). Whether torce-
trapib is able to influence this transfer is not known but this
would be a pathway worthy of further investigation.
We have demonstrated that administration of torcetrapib
to rats evokes an acute increase in blood pressure accom-
panied by a rise in plasma adrenal steroids. We believe it is
unlikely that the acute increase in blood pressure is mediated
via aldosterone or corticosterone for the following reasons.
First, as shown in Figure 7, acute administration of
aldosterone (1 or 10mgkg
 1, i.v.) in rats had no effect on
blood pressure under conditions where there was an acute
blood pressure response to torcetrapib. Second, administra-
tion of the mineralocorticoid receptor antagonist eplerenone
(20mgkg
 1, p.o.) did not reduce the pressor effect of
torcetrapib (data not shown). Finally, administration of the
3b-hydroxysteroid dehydrogenase inhibitor, trilostane,
completely prevented the torcetrapib-induced increase in
plasma aldosterone and corticosterone but did not reduce
the torcetrapib-induced increase in acute blood pressure
(Figure 6). It remains to be determined whether chronic
administration of torcetrapib to rats would have a sustained
effect on increasing blood pressure or adrenal steroid levels.
It is conceivable, that chronic elevation of aldosterone or
corticosterone in response to torcetrapib administration
would provide additional pathways for increasing blood
pressure via either genomic or non-genomic pathways
(Ullian, 1999; Schiffrin, 2006).
Figure 7 Exogenous aldosterone did not increase blood pressure.
Mean arterial blood pressure was measured in pentobarbital
(55mgkg
 1, i.p.)-anaesthetized rats that were administered aldos-
terone as sequential 30min infusions at 1 and 10mgkg
 1 or
equivalent volumes of vehicle (saline). Fifteen minutes later, both
groups of animals were administered torcetrapib (5mgkg
 1)a sa n
i.v. infusion of 30min duration. Each point represents the mean and
vertical lines represent the s.e. for the numbers of animals indicated
in parentheses.
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elevated plasma aldosterone concentration, hypertension and
increased cardiovascular events (Rocha and Funder, 2002;
Vasan et al., 2004; Connell and Davies, 2005). The relevance
of the acute blood pressure elevation and increase in plasma
aldosterone in response to torcetrapib reported herein to the
blood pressure elevation and adverse cardiovascular events
described in the ILLUMINATE trial is uncertain. Aldosterone is
a major regulator of sodium and water homoeostasis, thus
contributing to the maintenance of normal blood volume and
blood pressure. Increased aldosterone levels promote in-
creased sodium reabsorbtion with subsequent facilitated
potassium and hydrogen ion exchange, volume expansion
and elevated blood pressure. These classical effects of
aldosterone are mediated through binding of aldosterone to
the well-studied mineralocorticoid receptor (NR3C2) in
epithelial cells, primarily in the distal nephron of the kidney.
More recently, it has become appreciated that there are non-
classical aspects of aldosterone biology including synthesis at
sites other than the adrenal cortex; the presence of miner-
alocorticoid receptors in non-epithelial tissues including
heart, brain and blood vessels; and actions of aldosterone
via non-genomic mechanisms (Rocha and Funder, 2002;
Connell and Davies, 2005).
The strongest evidence that aldosterone is a contributor to
adverse cardiovascular events comes from clinical trials with
mineralocorticoid receptor antagonists. Two key studies,
Randomized Aldactone Evaluation Study (Pitt et al., 1999)
and Eplerenone Post-acute myocardial infarction Heart
failure Efficacy and Survival study (Pitt et al., 2003) demon-
strated benefits of mineralocorticoid receptor blockade in
patients with heart failure. Interestingly, in both studies,
benefits were observed shortly after randomization, suggest-
ing that aldosterone receptor blockade could be acting to
limit cardiac electrical disturbances.
Collectively, a considerable body of evidence is available to
support the concept that elevated plasma aldosterone
concentration is associated with adverse cardiovascular
effects and that reducing either the levels of aldosterone or
the effects of aldosterone is beneficial. Whether the in-
creased incidence of death and adverse cardiovascular events
reported in the ILLUMINATE trial were attributable to the
reported increase in plasma aldosterone is unknown. The
studies reported herein have shown an acute increase in
plasma aldosterone in rodents given torcetrapib. We are yet
to determine whether aldosterone levels remain elevated
with chronic administration of torcetrapib, and we do not
know whether this phenomenon is observed across a broad
range of species.
The mechanism for the acute blood pressure effect of
torcetrapib remains to be determined. Torcetrapib did not
have a direct action on vascular tone, as it did not contract
isolated arterial vascular segments in vitro and did not
enhance responses to other vasoactive agents. Torcetrapib
also did not affect the vascular endothelial nitric oxide
system as demonstrated by a lack of effect on ACh-induced
relaxation in isolated vascular preparations. Possible effects
of torcetrapib on smaller resistance vessels seem unlikely,
given that torcetrapib did not increase pressure in an isolated
perfused hindlimb preparation. Possible effects on cardiac
output were evaluated using high-frequency ultrasound at
the level of the ascending aorta. These studies showed no
remarkable change in cardiac output of anaesthetized rats at
doses where blood pressure is increased (data not shown).
Collectively, these data indicate that the mechanism does
not involve a direct effect on the cardiovascular system and
is most likely via a hormonal or endogenous mediator
system. Pharmacological studies have excluded activation of
angiotensin AT1 receptors, endothelin receptors or a1/a2-
adrenoceptors. Possible central effects of torcetrapib were
excluded because equivalent pressor effects of torcetrapib are
present in both normal and pithed anaesthetized rats in
which all central pathways are eliminated.
Administration of torcetrapib in a variety of animal
models evoked an acute increase in blood pressure and in
rats it was shown to increase plasma aldosterone and
corticosterone levels. Whether either or both of these
properties contributed to the adverse cardiovascular events
reported in the ILLUMINATE trial is unclear. It is also unclear
whether these properties of torcetrapib conspired against
determining significant beneficial effects of torcetrapib on
HDL and atherosclerotic plaque volume. In atherosclerosis-
prone mice, mineralocorticoid receptor blockade with
eplerenone not only reduced blood pressure but also
significantly reduced atherosclerotic lesion area by 35%
(Keidar et al., 2003). Thus, it is possible that elevated
aldosterone levels contribute to the development of athero-
sclerotic plaque. The question as to whether HDL elevation
Figure 8 Torcetrapib released aldosterone from isolated rat adrenal
cells. Aldosterone release was measured from primary adrenocortical
cells isolated from rat adrenal glands. Cells (B200000 per sample)
were incubated with angiotensin II (0.1mM), torcetrapib (1–30mM),
anacetrapib (0.1–10mM) or appropriate vehicle for 2h at 371C.
Following centrifugation, supernatants were assayed for aldosterone
by an enzyme-linked immunoassay. Each bar represents the mean
and vertical lines represent the s.e. for four samples.
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treatment of atherosclerosis remains open and should be
evaluated with a CETP inhibitor that does not carry inherent
cardiovascular liabilities.
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